Enantioselective inhibition of TNF-α release by thalidomide and thalidomide-analogues

Chirality

Volumn 8, Issue 5, 1996, Pages 390-396

  Wnendt, Stephan ^a   Finkam, Michael ^a   Winter, Werner ^a   Ossig, Joachim ^a   Raabe, Gerd ^b   Zwingenberger, Kai ^a  

^a GRÜNENTHAL GMBH   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

immunomodulation; lipopolysaccharide; optically pure drugs; stereochemistry; structure activity relations; thalidomide enantiomers; TNF

Indexed keywords

LIPOPOLYSACCHARIDE; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DRUG SELECTIVITY; ENANTIOMER; IMMUNOMODULATION; MONONUCLEAR CELL; PRIORITY JOURNAL; RACEMIC MIXTURE; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

CELLS, CULTURED; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KINETICS; MOLECULAR CONFORMATION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029990823     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-636X(1996)8:5<390::AID-CHIR6>3.0.CO;2-I     Document Type: Article

References (22)

1. Ochonisky, S., Verroust, J., Bastuji-Garin, S., Gherardi, R., Revuz, J. Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients. Arch. Dermatol. 130:65-69, 1994.
2. Sheskin, J. Thalidomide in the treatment of lepra reactions. Clin. Pharmacol. Ther. 6:303-306, 1965.
3. Ochonisky, S., Revuz, J. Thalidomide use in dermatology. Eur. J. Dermatol. 4:9-15, 1994.
4. Atra, E., Sato, E.I. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin. Exp. Rheumatol. 11:487-493, 1993.
5. Hamza, M. Treatment of Behcet's disease with thalidomide. In: Recent Advances in Behcet's Disease. Lehner, T., Barnes, C.G., eds. London, New York: Royal Society of Medicine Services, 1986:359-364.
6. Grinspan, D. Significant response of oral aphthosis to thalidomide treatment. J. Am. Acad. Dermatol. 12:85-90, 1985.
7. Grinspan, D., Blanco, G.F., Agüero, S. Treatment of aphthae with thalidomide. J. Am. Acad. Dermatol. 20:1060-1063, 1989.
8. Revuz, J., Guillaume J.-C., Janier, M., Hans, P., Marchand, C., Souteyrand, P., Bonnetblanc, J.-M., Claudy, A., Dallac, S., Klene, C., Crickx, B., Sanco-Garnier, H., Chaumeil, J.C. Crossover study of thalidomide vs. placebo in severe recurrent aphthous stomatitis. Arch. Dermatol. 126:923-927, 1990.
9. Sampaio, E.P., Sarno, E.N., Galilly, R., Cohn, Z.A., Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor-α production by stimulated human monocytes. J. Exp. Med. 173:699-703, 1991.
10. Sampaio, E.P., Kaplan, G., Miranda, A., Nery, J.A.C., Miguel, C.P., Viana, S.M., Sarno, E.N. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J. Infect. Dis. 168:408-414, 1993.
11. Moreira, A.L., Sampaio, E.P., Zmuidzinas, A., Frindt, P., Smith, K.A., Kaplan, G. Thalidomide exerts its inhibitory action on tumor necrosis factor a by enhancing mRNA degradation. J. Exp. Med. 177:1675-1680, 1993.
12. Brown, J.M., Davies, S.G. Chemical asymmetric synthesis. Nature 342:631-636, 1989.
13. Prasanna de Silva, A. Bright spies for chiral molecules. Nature 374:310-311, 1995.
14. Blaschke, G., Kraft, H.P., Fickentscher, F., Köhler, F. Chromatographische Racemattrennung von Thalidomid und Teratogene Wirkung der Enantiomere. Arzneimittelforschung 29:1640-1642, 1979.
15. Eriksson, T., Björkman, S., Roth, B., Fyge, A., Höglund, P. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 7:44-52, 1995.
16. Knabe, J., Omlor, G. Synthese der Racemate und der Enantiomere von 3-Alkyl-thalidomidanaloga und Bestimmung ihrer absoluten Konfiguration. Arch. Pharm. 322:499-505, 1989.
17. Büch, H.P., Omlor, G., Knabe, J. Stereoselektive Unterschiede der Zentral-nervös-depressorischen Wirkung in einer homologen Reihe von 3-Alkyl-thalidomid-analoga. Arzneimittelforschung 40:32-36, 1990.
18. Nishimura, K., Hashimoto, Y., Iwasaki, S. (S)-Form of α-methyl-N(α)-phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-α production by human leukaemia cell HL-60: Implication of optical resolution of thalidomide effects. Chem. Pharm. Bull. 42:1157-1159, 1994.
19. Shealy, F., Opliger C.E., Montgomery, J.A. Synthesis of D- and L-thalidomide and related studies. J. Pharm. Sci. 57:757-763, 1968.
20. Blaschke, G. Chromatographic resolution of chiral drugs on polyamines and cellulose triacetates. J. Liq. Chromatogr. 9:341-368, 1986.
21. Heger, W., Schmahl, H.-J., Klug, S., Felies, A., Nau, H., Merker, H.-J., Neubert, D. Embryotoxic effects of thalidomide derivatives in the non-human primate Callitrix jacchus. IV. Teratogenicity of μg/kg doses of the EM12 enantiomers. Teratogenesis Carcinog. Mutagen. 14:115-122, 1994.
22. Aboul-Enein, H.Y., Islam, M.R. Direct HPLC separation of thalidomide enantiomers using cellulose tris-4-methylphenyl benzoate chiral stationary phase. J. Liq. Chromatogr. 14:667-673, 1991.